secwatch.observer — SEC 8-K summary
======================================

Issuer:     HAEMONETICS CORP (HAE)
CIK:        0000313143
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0000313143-25-000006
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Haemonetics completes sale of whole blood assets to GVS for up to $67.8M
------------------------------------------------------------------------

- Total cash consideration up to $67.8M: $45.3M upfront (adjusted) plus up to $22.5M contingent.
- Contingent consideration tied to three-year sales growth and other milestones.
- Transaction closed on January 13, 2025, as previously disclosed in December 2024 8-K.
- Assets divested are within the Blood Center business unit's whole blood segment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/313143/000031314325000006/0000313143-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/313143/000031314325000006/hae-20250114.htm
  HTML page:      https://secwatch.observer/filing/0000313143-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer